Lipocine Inc. LPCN
1.52 USD -0.08 (-5.00%)
Regular-session close
1.50 -0.02 -1.31%
After hours · Nov 18, 6:51 PM ET
1.51 Day range 1.62
1.36 52-week range 12.37
- YTD
- -81.07%
- 1 year
- -55.03%
News
prnewswire.com Lipocine Doses First Participant in BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression LPCN 1154 is being developed as a 48-hour oral treatment intended for at-home use in postpartum depression Approximately 120 participants planned for the study, which incorporates insights from the…benzinga.com Lipocine Q3 EPS $(0.08) Beats $(0.32) Estimate, Sales $2.290M Beat $159.500K Estimate Lipocine (NASDAQ:LPCN) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.32) by 75 percent. This is a 86.44 percent increase over losses of $(0.59) per…
prnewswire.com Lipocine Announces Financial Results for the Third Quarter of 2026 SALT LAKE CITY, Nov. 5, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results…
zacks.com Here's Why You Should Add LPCN Stock to Your Portfolio Now Lipocine's Tlando royalties, Brlizio's phase III trial and broader pipeline offer multiple potential growth drivers and catalysts.
benzinga.com Canadian Approval Of Lipocine Drug Marks Progress for Oral Testosterone Options In Canada Health Canada has given the go-ahead to Lipocine Inc. (NASDAQ:LPCN) and its licensing partner, Verity Pharmaceuticals Inc., for TLANDO (testosterone undecanoate) capsules.
prnewswire.com Lipocine Announces Health Canada Approval of TLANDO® for Testosterone Replacement Therapy SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through…
zacks.com Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock? Lipocine (LPCN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
prnewswire.com Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression Study informed by encouraging exploratory efficacy findings and a favorable safety profile in the prior Phase 3 trial Approximately 120 participants with severe postpartum depression (PPD) planned;…
prnewswire.com Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that Company…
prnewswire.com Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 SALT LAKE CITY, Aug. 4, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced financial results…
prnewswire.com Lipocine Appoints Michael J. Grissinger to Board of Directors SALT LAKE CITY, Aug. 3, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral…
prnewswire.com Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4, 2026 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company focused on…
prnewswire.com Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral…
globenewswire.com Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and…
prnewswire.com Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral…
zacks.com Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates Lipocine (LPCN) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.35 per share a year ago.
prnewswire.com Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral…
defenseworld.net Mangoceuticals (NASDAQ:MGRX) versus Lipocine (NASDAQ:LPCN) Financial Contrast Mangoceuticals (NASDAQ: MGRX - Get Free Report) and Lipocine (NASDAQ: LPCN - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies…
defenseworld.net John Higuchi Buys 40,000 Shares of Lipocine (NASDAQ:LPCN) Stock Lipocine Inc. (NASDAQ: LPCN - Get Free Report) Director John Higuchi acquired 40,000 shares of the company's stock in a transaction that occurred on Tuesday, April 7th. The shares were bought at an…
defenseworld.net Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock Lipocine Inc. (NASDAQ: LPCN - Get Free Report) CEO Mahesh Patel bought 25,000 shares of the company's stock in a transaction on Monday, April 6th. The stock was bought at an average cost of $2.03 per…
benzinga.com What's Going On With Lipocine Stock On Monday? On Thursday, the company said LPCN 1154 did not meet its primary endpoint in a Phase 3 trial for postpartum depression (PPD).
